Delayed-Action Preparations

• 

  Subject Areas on Research

  • A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder. 
  • A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder. 
  • A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. 
  • A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. 
  • A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). 
  • A controlled-release strategy for the generation of cross-linked hydrogel microstructures. 
  • A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. 
  • A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. 
  • A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation. 
  • A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. 
  • A moldable sustained release bupivacaine formulation for tailored treatment of postoperative dental pain. 
  • A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. 
  • A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. 
  • A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. 
  • A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. 
  • A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. 
  • A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. 
  • A thermally responsive biopolymer for intra-articular drug delivery. 
  • Adinazolam sustained-release treatment of panic disorder: a double-blind study. 
  • Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. 
  • Advances in opioid antagonist treatment for opioid addiction. 
  • Amino Acid-Based Poly(ester urea)s as a Matrix for Extended Release of Entecavir. 
  • An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug. 
  • An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration. 
  • An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. 
  • An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. 
  • An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 
  • Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. 
  • Applications of elastin-like polypeptides in drug delivery. 
  • Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. 
  • Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. 
  • Beta-blocker therapy in non-cardiac surgery. 
  • Biomaterial-assisted local and systemic delivery of bioactive agents for bone repair. 
  • Bupropion SR in the naturalistic treatment of elderly patients with major depression. 
  • Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. 
  • Bupropion and Naltrexone in Methamphetamine Use Disorder. 
  • Bupropion sustained release: a therapeutic overview. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Cell-Demanded VEGF Release via Nanocapsules Elicits Different Receptor Activation Dynamics and Enhanced Angiogenesis 
  • Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. 
  • Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 
  • Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. 
  • Clinical effects of daily methamphetamine administration. 
  • Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. 
  • Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. 
  • Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. 
  • Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. 
  • Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. 
  • Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. 
  • Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. 
  • Contraceptive Methods and the Impact of Menstruation on Daily Functioning in Women with Sickle Cell Disease. 
  • Controlled Release of Vancomycin and Tigecycline from an Orthopaedic Implant Coating Prevents Staphylococcus aureus Infection in an Open Fracture Animal Model. 
  • Controlled apoptosis by a thermally toggled nanoscale amplifier of cellular uptake. 
  • Controlled release of biologics for the treatment of type 2 diabetes. 
  • Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. 
  • Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management. 
  • Controlled release of simvastatin from in situ forming hydrogel triggers bone formation in MC3T3-E1 cells. 
  • Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. 
  • Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. 
  • Criminal justice continuum for opioid users at risk of overdose. 
  • DepoDur extended-release epidural morphine: reshaping postoperative care. What perioperative nurses need to know. 
  • Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. 
  • Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. 
  • Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. 
  • Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. 
  • Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. 
  • Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. 
  • Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? 
  • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 
  • Does pretreatment anxiety predict response to either bupropion SR or sertraline? 
  • Does pretreatment insomnia or anxiety predict acute response to bupropion SR? 
  • Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension. 
  • Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. 
  • Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder. 
  • Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. 
  • Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. 
  • Effect of Extended Release Bupropion on Unilateral Ultrabrief Electroconvulsive Therapy Seizure Parameters in Major Depressive Disorder. 
  • Effect of an educational script on postpartum contraceptive use: a randomized controlled trial. 
  • Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. 
  • Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. 
  • Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. 
  • Effect of dipyridamole plus aspirin on hemodialysis graft patency. 
  • Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. 
  • Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. 
  • Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. 
  • Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. 
  • Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. 
  • Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study. 
  • Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 
  • Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. 
  • Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. 
  • Effects of paroxetine and venlafaxine XR on heart rate variability in depression. 
  • Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. 
  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale. 
  • Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension. 
  • Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. 
  • Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. 
  • Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. 
  • Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting. 
  • Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. 
  • Encapsulation and controlled release of retinol from silicone particles for topical delivery. 
  • Encapsulation in alginate-polymers improves stability and allows controlled release of the UFV-AREG1 bacteriophage. 
  • Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. 
  • Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide. 
  • Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. 
  • Erosion of microbicide formulation coating layers: effects of contact and shearing with vaginal fluid or semen. 
  • Evaluation of Weight-Based Dose During Transition From Immediate-Release to Extended-Release Tacrolimus in Kidney Transplant Recipients. 
  • Evaluation of a delivery system providing long-term release of cyclosporine. 
  • Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. 
  • Exparel for Postoperative Pain Management: a Comprehensive Review. 
  • Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial. 
  • Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. 
  • Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. 
  • Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. 
  • Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. 
  • Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment. 
  • Extended-release niacin for modifying the lipoprotein profile. 
  • Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. 
  • Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. 
  • Extended-release ranolazine: critical evaluation of its use in stable angina. 
  • Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. 
  • Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. 
  • Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. 
  • Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. 
  • Functional status in depressed patients: the relationship to disease severity and disease resolution. 
  • Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. 
  • Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models. 
  • Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. 
  • Getting there is half the battle: recent advances in delivering therapeutics 
  • Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. 
  • History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. 
  • History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 
  • Hormone release and abortifacient effectiveness of a newly developed silastic device containing 15-ME-PGF2alpha methyl ester in concentrations of 0.5% and 1.0%. 
  • Imaging of recurrent intramuscular granulomatous masses induced by depot injection of leuprorelin. 
  • Implantable, polymeric systems for modulated drug delivery. 
  • In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. 
  • Increase in work productivity of depressed individuals with improvement in depressive symptom severity. 
  • Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. 
  • Inhibition of epidural scar formation after lumbar laminectomy in the rat. 
  • Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. 
  • Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. 
  • Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. 
  • Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. 
  • Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. 
  • Lipid-coated microgels for the triggered release of doxorubicin. 
  • Long-acting injectable naltrexone for the treatment of alcohol dependence. 
  • Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. 
  • Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. 
  • Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. 
  • Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. 
  • Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. 
  • Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. 
  • Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Menetrier's disease treated with octreotide long-acting release. 
  • Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. 
  • Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. 
  • Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. 
  • Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity Disorder. 
  • Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. 
  • Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. 
  • PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. 
  • PLGA and PHBV Microsphere Formulations and Solid-State Characterization: Possible Implications for Local Delivery of Fusidic Acid for the Treatment and Prevention of Orthopaedic Infections 
  • Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. 
  • Paroxetine in the treatment of generalised anxiety disorder. 
  • Paroxetine: safety and tolerability issues. 
  • Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone. 
  • Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. 
  • Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. 
  • Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with or without a gonadotropin-releasing hormone agonist. 
  • Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. 
  • Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. 
  • Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. 
  • Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. 
  • Predicted patient demand for a new delivery system for glaucoma medicine. 
  • Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. 
  • Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. 
  • Protease degradable tethers for controlled and cell-mediated release of nanoparticles in 2-and 3-dimensions 
  • Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. 
  • Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. 
  • Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. 
  • Real-world effectiveness of long-acting injectable antipsychotics to reduce 90-day and annual readmission in psychotic disorders: insights from a state psychiatric hospital. 
  • Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial. 
  • Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. 
  • Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. 
  • Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR. 
  • Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. 
  • Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. 
  • Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. 
  • Retinal venous occlusion associated with depot medroxyprogesterone acetate. 
  • Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. 
  • Review: implants. 
  • Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. 
  • Safety of nifedipine in angina pectoris: a meta-analysis. 
  • Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. 
  • Saliva nicotine as an index of plasma levels in nicotine skin patch users. 
  • Scanning electron microscopy and X-ray microanalysis of foreign bodies associated with Silastic implants in humans. 
  • Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 
  • Serotonin syndrome after a massive overdose of controlled-release paroxetine. 
  • Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage. 
  • Single-dose extended-release epidural morphine for pain after hip arthroplasty. 
  • Single-dose extended-release epidural morphine for pain following hip arthroplasty. 
  • Slow-release nanoparticle-encapsulated delivery system for laryngeal injection. 
  • Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. 
  • Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. 
  • Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers. 
  • Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. 
  • Sustained Release Corticosteroid Therapy for Noninfectious Uveitis. 
  • Sustained in vivo gene delivery from agarose hydrogel prolongs nonviral gene expression in skin. 
  • Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. 
  • Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. 
  • Sustained release of antibiotics from injectable and thermally responsive polypeptide depots. 
  • Sustained release of nerve growth factor from biodegradable polymer microspheres. 
  • Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. 
  • Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). 
  • Temperature-sensitive hydrogels with SiO2-Au nanoshells for controlled drug delivery. 
  • The abortifacient effectiveness and plasma prostaglandin concentrations with 15(S)-15-methyl prostaglandin F2alpha methyl ester-containing vaginal silastic devices. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The impact of short-term depot-medroxyprogesterone acetate treatment on resting metabolic rate. 
  • The nicotine patch in smoking cessation. A randomized trial with telephone counseling. 
  • The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. 
  • Thermo-responsive systems for controlled drug delivery 
  • Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. 
  • Tiotropium (Spiriva) for COPD. 
  • Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. 
  • Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. 
  • Treatment of hyperlipidemia with combined niacin-statin regimens. 
  • Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. 
  • Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. 
  • Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. 
  • Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. 
  • Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
  • Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology